Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

被引：0

作者：

Guttman-Yassky, Emma ^{[1
]}

Weidinger, Stephan ^{[2
]}

Simpson, Eric ^{[3
]}

Gooderham, Melinda ^{[4
,5
]}

Irvine, Alan ^{[6
]}

Spelman, Lynda ^{[7
,8
]}

Silverberg, Jonathan ^{[9
]}

Elmaraghy, Hany ^{[10
]}

DeLuca-Carter, Louise ^{[10
]}

Piruzeli, Maria Lucia Buziqui ^{[10
]}

Hu, Chaoran ^{[10
]}

Yang, Fan Emily ^{[10
]}

Pierce, Evangeline ^{[10
]}

Bardolet, Laia ^{[11
]}

Thaci, Diamant ^{[12
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Hosp Schleswig Holstein, Kiel, Germany

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Prob Med Res, SKiN Dermatol, Peterborough, ON, Canada

[5] Queens Univ, Peterborough, ON, Canada

[6] Childrens Hlth Ireland, Dublin, Ireland

[7] Verac Clin Res, Woolloongabba, Qld, Australia

[8] Prob Med Res, Woolloongabba, Qld, Australia

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA

[10] Eli Lilly & Co, Indianapolis, IN 46285 USA

[11] Almirall SA, Barcelona, Spain

[12] Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷

关键词：

atopic dermatitis; efficacy; lebrikizumab; phase; 3; trials; safety;

D O I：

10.1093/bjd/ljad498.005

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

494

引用

页码：II3 / II4

页数：2

共 50 条

[31] Conjunctivitis does not increase with longer duration of lebrikizumab exposure in patients with moderate-to-severe atopic dermatitis
Armstrong, April
Wollenberg, Andreas
de Bruin-Weller, Marjolein
Lio, Peter
Natalie, Chitra R.
Zhao, Fangyi
Atwater, Amber Reck
Jimenez, Gemma
Chu, Chia-Yu
Vestergaard, Christian
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II5 - II6
[32] Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
Gold, Linda Stein
Thaci, Diamant
Thyssen, Jacob P.
Gooderham, Melinda
Laquer, Vivian
Moore, Angela
Natalie, Chitra R.
Zhao, Fangyi
Meskimen, Eric
Elmaraghy, Hany
Montmayeur, Sonia
Gallo, Gaia
Jimenez, Gemma
de Bruin-Weller, Marjolein
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (04) : 595 - 607
[33] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Paller, Amy S.
Flohr, Carsten
Eichenfield, Lawrence F. F.
Irvine, Alan D. D.
Weisman, Jamie
Soung, Jennifer
Correia, Ana Pinto
Natalie, Chitra R. R.
Capriles, Claudia Rodriguez
Pierce, Evangeline
Reifeis, Sarah
Lima, Renata Gontijo
Tubau, Clara Armengol
Laquer, Vivian
Weidinger, Stephan
DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
[34] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Amy S. Paller
Carsten Flohr
Lawrence F. Eichenfield
Alan D. Irvine
Jamie Weisman
Jennifer Soung
Ana Pinto Correia
Chitra R. Natalie
Claudia Rodriguez Capriles
Evangeline Pierce
Sarah Reifeis
Renata Gontijo Lima
Clara Armengol Tubau
Vivian Laquer
Stephan Weidinger
Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
[35] Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial (ADhere)
Simpson, Eric L. L.
Gooderham, Melinda
Wollenberg, Andreas
Weidinger, Stephan
Armstrong, April
Soung, Jennifer
Ferrucci, Silvia
Lima, Renata Gontijo
Witte, Michael M. M.
Xu, Wen
ElMaraghy, Hany
Natalie, Chitra R. R.
Pierce, Evangeline
Blauvelt, Andrew
ADhere Investigators
JAMA DERMATOLOGY, 2023, 159 (02) : 182 - 191
[36] Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
Linda Stein Gold
Diamant Thaçi
Jacob P. Thyssen
Melinda Gooderham
Vivian Laquer
Angela Moore
Chitra R. Natalie
Fangyi Zhao
Eric Meskimen
Hany Elmaraghy
Sonia Montmayeur
Gaia Gallo
Gemma Jimenez
Marjolein de Bruin-Weller
American Journal of Clinical Dermatology, 2023, 24 : 595 - 607
[37] Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis
Alexis, Andrew
Ardern-Jones, Michael
Chovatiya, Raj
Flohr, Carsten
Irvine, Alan
AlMurrawi, Muna
Atwater, Amber Reck
Ding, Yuxin
Qiao, Meihua
Pierce, Evangeline
Pau-Charles, Ignasi
Heath, Candrice
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II20 - II21
[38] Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
Zirwas, Matthew J.
Boguniewicz, Mark
Rosmarin, David
Fuxench, Zelma Chiesa
Warren, Richard B.
Torres, Tiago
de Bruin-Weller, Marjolein
Dawson, Zach
Atwater, Amber Reck
Elmaraghy, Hany
Pierce, Evangeline
Bardolet, Laia
Zhong, Jinglin
Armstrong, April W.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 54 - 56
[39] EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Worrell, Richard
Paller, Amy S.
Siegfried, Elaine C.
Simpson, Eric L.
Wollenberg, Andreas
Gonzalez, Mercedes E.
Sidbury, Robert
Lockshin, Benjamin
Dubost-Brama, Ariane
Bansal, Ashish
INTERNAL MEDICINE JOURNAL, 2022, 52 : 31 - 32
[40] Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
Mareschal, Adrien
Puzenat, Eve
Aubin, Francois
ACTA DERMATO-VENEREOLOGICA, 2020, 100 (01)

← 1 2 3 4 5 →